Paroxetine-induced increase in LDL cholesterol levels

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Psychiatry

Background:

• Paroxetine is a commonly prescribed medication for various psychiatric disorders.
• The impact of paroxetine on lipid profiles, particularly low-density lipoprotein cholesterol (LDL-C), requires thorough investigation.

Purpose of the Study:

• To evaluate the short-term effects of paroxetine on LDL-C levels in healthy controls (HCs) and patients with panic disorder (PD).
• To determine if paroxetine administration causes a clinically significant increase in LDL-C.

Main Methods:

• A study involving 24 male HCs and 9 male PD patients.
• Blood samples were collected at baseline, after 8 weeks of paroxetine treatment, and post-discontinuation.
• LDL-C levels were measured using standardized laboratory procedures.

Main Results:

• Paroxetine administration resulted in a mean 9% increase in LDL-C per subject in both HCs and PD patients.
• LDL-C levels returned to baseline after paroxetine discontinuation, suggesting a causal relationship.
• 36% of low-risk subjects experienced an LDL-C increase above 2.7 mmol/L (100 mg/dL).

Conclusions:

• Short-term paroxetine use can lead to a clinically significant, albeit reversible, increase in LDL-C.
• This LDL-C elevation may pose cardiovascular risks, especially in psychiatric patients with existing coronary heart disease (CHD).
• Further research is needed to explore the effects of longer treatment durations and higher doses of paroxetine on LDL-C.